JP2025501169A - 呼吸刺激薬非経口製剤 - Google Patents

呼吸刺激薬非経口製剤 Download PDF

Info

Publication number
JP2025501169A
JP2025501169A JP2024539090A JP2024539090A JP2025501169A JP 2025501169 A JP2025501169 A JP 2025501169A JP 2024539090 A JP2024539090 A JP 2024539090A JP 2024539090 A JP2024539090 A JP 2024539090A JP 2025501169 A JP2025501169 A JP 2025501169A
Authority
JP
Japan
Prior art keywords
formulation
substituted
compound
parenteral formulation
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024539090A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501169A5 (enExample
Inventor
ペルゴリッジ，ジョセフ，ブイ．
ディアナ，フランク
チェン，ジャーイー
ドッド，デヴォン，イー．
アギェマン，イサック
Original Assignee
エナラーレ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エナラーレ セラピューティクス インコーポレイテッド filed Critical エナラーレ セラピューティクス インコーポレイテッド
Publication of JP2025501169A publication Critical patent/JP2025501169A/ja
Publication of JP2025501169A5 publication Critical patent/JP2025501169A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2024539090A 2021-12-27 2022-12-23 呼吸刺激薬非経口製剤 Pending JP2025501169A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163293985P 2021-12-27 2021-12-27
US63/293,985 2021-12-27
US202263313472P 2022-02-24 2022-02-24
US63/313,472 2022-02-24
PCT/US2022/053935 WO2023129502A1 (en) 2021-12-27 2022-12-23 Respiratory stimulant parenteral formulations

Publications (2)

Publication Number Publication Date
JP2025501169A true JP2025501169A (ja) 2025-01-17
JP2025501169A5 JP2025501169A5 (enExample) 2026-01-05

Family

ID=86992921

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024539090A Pending JP2025501169A (ja) 2021-12-27 2022-12-23 呼吸刺激薬非経口製剤

Country Status (9)

Country Link
US (1) US20230210857A1 (enExample)
EP (1) EP4456900A4 (enExample)
JP (1) JP2025501169A (enExample)
KR (1) KR20240150426A (enExample)
AU (1) AU2022426492A1 (enExample)
CA (1) CA3242509A1 (enExample)
MX (1) MX2024008162A (enExample)
TW (1) TW202333732A (enExample)
WO (1) WO2023129502A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4543455A4 (en) * 2022-06-24 2026-06-03 Enalare Therapeutics Inc METHODS OF TREATMENT FOR NEUROLOGICAL VENTILATORY FAILURE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69729880T3 (de) * 1996-12-24 2012-05-10 Biogen Idec Ma Inc. Stabile flüssige interferon-zubereitungen
SG10201601507YA (en) * 2010-11-29 2016-04-28 Galleon Pharmaceuticals Inc Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
US20120295911A1 (en) * 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
AU2012250050B2 (en) * 2011-04-28 2017-04-06 Platform Brightworks Two, Ltd. Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
BR112015011213A2 (pt) * 2012-11-15 2017-08-29 Galleon Pharmaceuticals Inc Composto, composição farmacêutica, método de prevenção ou tratamento de um distúrbio ou doença de controle respiratório em um indivíduo, método de prevenção de desestabilização ou de estabilização do ritmo respiratório em um indivíduo, método de preparação de o,n-dimetil-n-[4-(n-propilamina)-6-(prop-2-inilamina)-[1,3,5]triazin-2-il]-hidroxilamina, e composição.
GB201502412D0 (en) * 2015-02-13 2015-04-01 Canbex Therapeutics Ltd Therapeutic use

Also Published As

Publication number Publication date
EP4456900A1 (en) 2024-11-06
TW202333732A (zh) 2023-09-01
WO2023129502A1 (en) 2023-07-06
KR20240150426A (ko) 2024-10-15
US20230210857A1 (en) 2023-07-06
MX2024008162A (es) 2024-09-17
EP4456900A4 (en) 2025-12-24
CA3242509A1 (en) 2023-07-06
AU2022426492A1 (en) 2024-07-18

Similar Documents

Publication Publication Date Title
US20230310440A1 (en) Respiratory stimulant nasal formulations
EP1371355B1 (en) UV-protection formulations
JP4344241B2 (ja) トリアジン誘導体、およびサンスクリーンとしてのその使用
KR102382188B1 (ko) NamPT 억제용 신규 화합물 및 이를 포함하는 조성물
US20250114370A1 (en) Methods and compositions for treating drug overdose
US20250032496A1 (en) Methods of treating respiratory depression modulated by a non-opioid agent
KR102345271B1 (ko) 미용 조성물의 안정화
JP2024517463A (ja) ニコチンアミドアデニンジヌクレオチド（ｎａｄ）組成物、それらの製造方法、及びそれらの使用方法
KR20240150426A (ko) 비경구 호흡 자극제 제형
CA3217969A1 (en) Nicotinamide adenine dinucleotide (nad) compositions, methods of manufacturing thereof, and methods of use thereof
US20230414624A1 (en) Methods of treating neurological ventilatory insufficiency
US20240238303A1 (en) Large-conductance potassium channel modulators, compositions thereof, methods of manufacturing thereof, and methods of use thereof
CN118829433A (zh) 呼吸刺激剂肠胃外制剂
TW202529771A (zh) 用於治療藥物過量的方法及組合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251219